Literature DB >> 30536438

Progress of polio eradication and containment requirements after eradication.

M Steven Oberste1.   

Abstract

Wild poliovirus (WPV) is nearing eradication, and only three countries have never interrupted WPV transmission (Pakistan, Afghanistan, and Nigeria). WPV2 was last detected in 1999, and it was declared eradicated in 2015. WPV3 has not been detected since 2012. Since 2016, WPV1 has been detected in only two countries (Afghanistan and Pakistan), with only 22 cases reported in 2017 and 12 cases reported in 2018 (as of July 10). Because of WPV2 eradication and the risk of emergence of type 2 vaccine-derived polioviruses from continued use of trivalent oral polio vaccine (OPV), trivalent OPV was replaced by bivalent OPV (types 1 and 3) in a globally coordinated effort in 2016. WPV2 eradication and trivalent OPV cessation also mean that breach of containment in a facility working with type 2 poliovirus is now a major risk to reseed type 2 circulation in the community. As a result, the World Health Organization has developed a "Global Action Plan to minimize poliovirus facility-associated risk after type-specific eradication of wild polioviruses and sequential cessation of oral polio vaccine use." Because poliovirus has long been used as a standard for qualification of intravenous immunoglobulin, disinfectant products, and sanitation methods, poliovirus containment has implications far beyond poliovirus laboratories.
© 2018 AABB.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30536438      PMCID: PMC8963859          DOI: 10.1111/trf.15018

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  13 in total

1.  Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016.

Authors:  Lee M Hampton; Margaret Farrell; Alejandro Ramirez-Gonzalez; Lisa Menning; Stephanie Shendale; Ian Lewis; Jennifer Rubin; Julie Garon; Jennifer Harris; Terri Hyde; Steven Wassilak; Manish Patel; Robin Nandy; Diana Chang-Blanc
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-09-09       Impact factor: 17.586

Review 2.  Complexities of Viral Mutation Rates.

Authors:  Kayla M Peck; Adam S Lauring
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

Review 3.  Polio eradication: the OPV paradox.

Authors:  Walter R Dowdle; Esther De Gourville; Olen M Kew; Mark A Pallansch; David J Wood
Journal:  Rev Med Virol       Date:  2003 Sep-Oct       Impact factor: 6.989

4.  Risk assessment, risk management and risk-based monitoring following a reported accidental release of poliovirus in Belgium, September to November 2014.

Authors:  Erwin Duizer; Saskia Rutjes; Ana Maria de Roda Husman; Jack Schijven
Journal:  Euro Surveill       Date:  2016

Review 5.  Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication.

Authors:  Mark A McKinlay; Marc S Collett; Jeffrey R Hincks; M Steven Oberste; Mark A Pallansch; Hiromasa Okayasu; Roland W Sutter; John F Modlin; Walter R Dowdle
Journal:  J Infect Dis       Date:  2014-11-01       Impact factor: 5.226

6.  Twenty-Eight Years of Poliovirus Replication in an Immunodeficient Individual: Impact on the Global Polio Eradication Initiative.

Authors:  Glynis Dunn; Dimitra Klapsa; Thomas Wilton; Lindsay Stone; Philip D Minor; Javier Martin
Journal:  PLoS Pathog       Date:  2015-08-27       Impact factor: 6.823

7.  Response to a wild poliovirus type 2 (WPV2)-shedding event following accidental exposure to WPV2, the Netherlands, April 2017.

Authors:  Erwin Duizer; Wilhelmina Lm Ruijs; Charlie P van der Weijden; Aura Timen
Journal:  Euro Surveill       Date:  2017-05-25

Review 8.  Vaccine-derived polioviruses.

Authors:  Cara C Burns; Ousmane M Diop; Roland W Sutter; Olen M Kew
Journal:  J Infect Dis       Date:  2014-11-01       Impact factor: 5.226

9.  Progress Toward Polio Eradication - Worldwide, January 2016-March 2018.

Authors:  Farrah Khan; S Deblina Datta; Arshad Quddus; John F Vertefeuille; Cara C Burns; Jaume Jorba; Steven G F Wassilak
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-05-11       Impact factor: 17.586

10.  Prolonged Excretion of Poliovirus among Individuals with Primary Immunodeficiency Disorder: An Analysis of the World Health Organization Registry.

Authors:  Grace Macklin; Yi Liao; Marina Takane; Kathleen Dooling; Stuart Gilmour; Ondrej Mach; Olen M Kew; Roland W Sutter
Journal:  Front Immunol       Date:  2017-09-25       Impact factor: 7.561

View more
  1 in total

1.  Use of guanidine thiocyanate-based nucleic acid extraction buffers to inactivate poliovirus in potentially infectious materials.

Authors:  Michelle J Honeywood; Stacey Jeffries-Miles; Kimberly Wong; Chelsea Harrington; Cara C Burns; M Steven Oberste; Michael D Bowen; Everardo Vega
Journal:  J Virol Methods       Date:  2021-08-09       Impact factor: 2.623

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.